Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Euronext Bruxelles  >  Ablynx    ABLX   BE0003877942

ABLYNX (ABLX)

SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsSector news 

ABLYNX (D) : RECEIVES EUR 5 MILLION IN MILESTONE PAYMENT FROM ALZHEIMER'S DISEASE COLLABORATION WITH BOEHRINGER INGELHEIM

share with twitter share with LinkedIn share with facebook
share via e-mail
0
06/27/2011 | 07:05am CET

GHENT, Belgium, 27 June 2011 - Ablynx [Euronext Brussels: ABLX] today announced that it has earned a ?5 million milestone payment following Boehringer Ingelheim's decision to initiate development  with the lead Nanobody candidate that was selected in May 2010.

 

In January 2007, Boehringer Ingelheim and Ablynx announced a worldwide research and licensing agreement to discover and develop new therapies for Alzheimer's disease using Ablynx's Nanobodies against a single disease target. The collaboration has a potential value of $265 million in upfront and milestone payments plus undisclosed royalties on product sales. Boehringer Ingelheim is solely responsible for the development, manufacturing and commercialisation of any products resulting from the collaboration.

 

"We are delighted that Boehringer Ingelheim is making further progress with the Nanobody lead candidate which has the potential to be a first-in-class therapy for Alzheimer's disease and we look forward to this product advancing into the clinic in 2012. This is the second milestone payment that we have received as part of our Alzheimer's research collaboration with Boehringer Ingelheim," said Dr. Edwin Moses, Chairman and CEO of Ablynx. He added: "This programme illustrates the wide applicability and advantages of our Nanobody platform in addressing diseases as complex as Alzheimer's."

 

 

For more information, please contact Ablynx:
Dr Edwin Moses
Chairman and CEO
t:   +32 (0)9 262 00 07
m: +44 (0)7771 954 193 /
     +32 (0)473 39 50 68
e:  edwin.moses@ablynx.com:
mailto:edwin.moses@ablynx.com

 

Marieke Vermeersch
Investor Relations Manager
t:   +32 (0)9 262 00 82
m: +32 (0)479 49 06 03
e:  marieke.vermeersch@ablynx.com :
mailto:marieke.vermeersch@ablynx.com%20

 

Complete version of the press release:
http://hugin.info/137912/R/1526010/461786.pdf



This announcement is distributed by Thomson Reuters on behalf of Thomson Reuters clients.

The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and other applicable laws; and
(ii) they are solely responsible for the content, accuracy and originality of the
information contained therein.

Source: Ablynx via Thomson Reuters ONE

HUG#1526010
share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on ABLYNX
11/30 ABLYNX : Achieves first milestone as part of collaboration with novo nordisk
11/23 ABLYNX : 23/11/2016 ablynx announces results for the first nine months of 2016 a..
11/23 ABLYNX : Announces results for the first nine months of 2016 and a year-to-date ..
11/18ABLYNX NV : quaterly earnings release
11/18 ABLYNX : 18/11/2016 fmr llc announce 9.10% shareholding in ablynx
11/18 ABLYNX : Fmr llc announce 9.10% shareholding in ablynx
11/10 ABLYNX : 10/11/2016 ablynx announces warrant exercise
11/10 ABLYNX : Announces warrant exercise
11/09 ABLYNX : To present at the jefferies london healthcare conference 2016
10/27 ABLYNX : Patent Issued for Method for Producing Solid Formulations Comprising Im..
More news
Sector news : Biotechnology & Medical Research - NEC
12/03DJJOHNSON & JOHNSON : Boosts Actelion Bid -Bloomberg
12/02 Pharma execs weigh in on possible changes under Trump
11/30 ACTELION : Rejecting J&J could leave Actelion with 'lot of explaining to do'
11/28 Actelion's ambitious independent-minded CEO will drive up takeover price
11/26DJWHAT'S NEWS : Business & Finance -- WSJ
More sector news : Biotechnology & Medical Research - NEC
News from SeekingAlpha
11/23 Ablynx NV reports 9M results
10/17 ARGENX : The New Ablynx?
10/03 A European Biotech Stock Basket For 2016 - Update
08/29 Why Abbvie Won't Pull A Galapagos On Ablynx
08/25 Ablynx, My Favorite Belgian (Biotech) Stock
Advertisement
Financials (€)
Sales 2016 80,1 M
EBIT 2016 -22,1 M
Net income 2016 -6,33 M
Finance 2016 30,8 M
Yield 2016 -
P/E ratio 2016 -
P/E ratio 2017
EV / Sales 2016 7,29x
EV / Sales 2017 15,0x
Capitalization 614 M
More Financials
Chart ABLYNX
Duration : Period :
Ablynx Technical Analysis Chart | ABLX | BE0003877942 | 4-Traders
Full-screen chart
Technical analysis trends ABLYNX
Short TermMid-TermLong Term
TrendsBullishBearishBearish
Technical analysis
Income Statement Evolution
More Financials
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 6
Average target price 15,0 €
Spread / Average Target 49%
Consensus details
EPS Revisions
More Estimates Revisions
Managers
NameTitle
Edwin Moses Chief Executive Officer & Executive Director
Peter John Fellner Chairman
Wim Ottevaere Chief Financial Officer
Antonin Rollet de Fougerolles Chief Scientific Officer
Robert K. Zeldin Chief Medical Officer
More about the company
Sector and Competitors
1st jan.Capitalization (M$)
ABLYNX-36.62%658
INCYTE CORPORATION-1.14%20 197
QUINTILES IMS HOLDINGS..12.99%19 099
CELLTRION, INC.--.--%9 992
SEATTLE GENETICS, INC.48.48%9 433
LONZA GROUP AG8.34%9 288
More Results